Advertisement

Pathophysiologie — ANF-System

  • M. Haass
Part of the Aktuelle Therapieprinzipien in Kardiologie und Angiologie book series (THERAPIEPRINZ.)

Zusammenfassung

Den zahlreichen bei Herzinsuffizienz stimulierten vasopressorischen Systemen steht als bedeutsamer endogener Gegenspieler der atriale natriuretische Faktor (ANF) gegenüber.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Anderson JV, Woodruff PWR, Bloom SR (1988) The effect of treatment of congestive heart failure on plasma atrial natriuretic peptide concentration: a longitudinal study. Br Heart J 59:207–211PubMedCrossRefGoogle Scholar
  2. Awazu M, Imada T, Kon V, Inagami T, Ichikawa I (1989) Role of endogenous atrial natriuretic peptide in congestive heart failure. Am J Physiol 257:R641-R646PubMedGoogle Scholar
  3. Ballermann BJ, Brenner BM (1986) Role of atrial peptides in body fluid homeostasis. Cir Res 58:619–630Google Scholar
  4. Bold AJ de, Borenstein HB, Veress AT, Sonnenberg H (1981) A rapid and potent response to intravenous injection of atrial myocardial extracts in rats. Life Sci 28:89–94PubMedCrossRefGoogle Scholar
  5. Dietz R, Haass M, Kübler W (1989) Atrial natriuretic factor — its possible role in hypertension and heart failure. Am J Hypertens 2:29S-33SPubMedGoogle Scholar
  6. Dietz R, Haass M, Osterziel KJ (1991) Atrial natriuretic factor and arginine vasopressin. Lea & Febiger, Indianapolis (Progress in cardiology, vol 4/1, pp 113–133)Google Scholar
  7. Espiner EA, Richards AM (1989) Atrial natriuretic peptide: an important factor in sodium and blood pressure regulation. Lancet 1:707–710PubMedCrossRefGoogle Scholar
  8. Gauer OH, Henry JP (1963) Circulatory basis of fluid volume control. Physiol Rev 43:423–481PubMedGoogle Scholar
  9. Goetz KL (1988) Physiology and pathophysiology of atrial peptides. Am J Physiol 254:E1-E15PubMedGoogle Scholar
  10. Goetz KL (1990) Evidence that atriopeptin is not a physiological regulator of sodium excretion. Hypertension 15:9–19PubMedGoogle Scholar
  11. Gottlieb SS, Kukin ML, Ahern D, Packer M (1989) Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 13:1534–1539PubMedCrossRefGoogle Scholar
  12. Haass M, Dietz R, Fischer ThA, Lang RE, Kübler W (1988 a) Role of right and left atrial dimensions for release of atrial natriuretic peptide in left-sided valvular heart disease and idopathic dilated cardiomyopathy. Am J Cardiol 62:764–770Google Scholar
  13. Haass M, Dietz R, Kübler W (1988b) Hat die Plasma-ANF-Bestimmung eine diagnostische oder prognostische Bedeutung bei Patienten mit Herzvitien? Z Kardiol [Suppl 2] 77:55–60Google Scholar
  14. Haass M, Fischer THA, Hänze J, Saggau W, Lang RE, Dietz R, (1990) Atrial natriuretic peptidemRNA in patients with heart disease. Am J Hypertens 3:234–236PubMedGoogle Scholar
  15. Needleman P, Blaine EH, Greenwald JE, Michener ML, Saper CE, Stockmann PT, Tolunay HE (1989) The biochemical pharmacology of atrial peptides. Annu Rev Pharmacol Toxicol 29:23–54PubMedCrossRefGoogle Scholar
  16. Northridge DB, Jardine AG, Alabaster CT et al. (1989) Effects of UK 69578: a novel triopepti-dase inhibitor. Lancet 11:591–593CrossRefGoogle Scholar
  17. Yasue H, Obata K, Okumura K et al. (1989) Increased secretion of atrial natriuretic polypeptide from the left ventricle in patients with düated cardiomyopathy. J Clin Invest 83:46–51PubMedCrossRefGoogle Scholar
  18. Zeidel ML, Brenner BM (1987) Actions of atrial natriuretic peptide on the kidney. Semin Nephrol 7:91–97PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • M. Haass

There are no affiliations available

Personalised recommendations